EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Gastrointestinal CancerColon CancerRectal CancerAnal CancerEsophageal CancerStomach CancerAppendix CancerPancreas CancerLiver CancerNeuroendocrine Tumors
Interventions
OTHER

EQUITY GI

"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."

Trial Locations (1)

44106

RECRUITING

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER